Clinical cases employing novel agents in Hodgkin lymphoma
Clinical cases employing novel agents in Hodgkin lymphoma
Chronic lymphocytic leukaemia: Transition to a new era
The role of the microenvironment and novel therapies in CLL
Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer
Identifying myeloid-driven biologies
Metastasis intiation mediated by thrombospondin 2
AML17 Trial results: maximum dosage of daunorubicin in AML
AML during pregancy
BSH 2016: Expert discussion on idelalisib
Next-generation sequencing in the lymphoid malignancies
Risk of breast cancer after chest radiotherapy may be affected by genetics